Compare LMNR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | RNA |
|---|---|---|
| Founded | 1893 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 217.5M |
| IPO Year | 2005 | 2025 |
| Metric | LMNR | RNA |
|---|---|---|
| Price | $12.68 | $12.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | $20.00 | ★ $69.26 |
| AVG Volume (30 Days) | 53.4K | ★ 340.0K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,723,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $13.95 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $11.95 |
| 52 Week High | $17.11 | $73.06 |
| Indicator | LMNR | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 29.04 |
| Support Level | $12.54 | $12.85 |
| Resistance Level | $13.60 | $14.80 |
| Average True Range (ATR) | 0.39 | 0.65 |
| MACD | 0.01 | 0.74 |
| Stochastic Oscillator | 38.05 | 20.69 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.